Co-founder of Geneoscopy, Andrew graduated from Cornell University with a Bachelor’s degree in Applied Economics & Management and a specialization in Finance. He received an MBA in Health Care Management and Entrepreneurial Management from The Wharton School. Andrew began his career as a financial analyst in J.P. Morgan’s healthcare investment banking group, working primarily on M&A and capital markets transactions. Andrew also worked as an associate at Lindsay Goldberg, a middle-market private equity firm focused on partnering with family-owned businesses.

Jim has over forty years of experience in healthcare, including twenty-two years at Boehringer Mannheim Diagnostics (now Roche Diagnostics). Jim has led a number of healthcare diagnostic start-ups. From 2002 to 2007, he served as President and CEO of HemoSense, a point-of-care diagnostics company which he successfully took public (AMEX: HEM) and sold two years later to Alere (NYSE: ALR). He has also served in leadership roles at several other start-ups, including Nexus Dx (now Samsung), Alverix (now Becton Dickinson), and Micronics (now SONY). Jim is a Managing Director of Synchrony Bio, a seed stage biomedical and life science venture fund. Jim also serves on the board of several other biotechnology and diagnostics companies including Trinity Biotech, Kypha, and Abram Scientific.

Bobby has almost 40 years in the pharmaceutical and venture capital business. He is currently Managing Director of Paula and Rodger Riney Foundation, General Partner in Cultivation Capital Life Sciences Fund II and President and CEO of Euclises Pharmaceuticals. He was formerly President and CEO of Coronado Biosciences (NASDAQ: CNDO) where he led the effort to take the company public, prior to that he was VP of oncology at Covidien Pharmaceuticals (now Mallinckrodt), and prior to that he was the executive vice president, research and development, and Chief Scientific Officer at Indevus Pharmaceuticals (NASDAQ: IDEV). He previously held senior drug development positions at DuPont Merck Pharmaceutical Company and Merrell Dow Pharmaceuticals. He serves on the boards of Immunophotonics, Endevica Biosciences and BioVentures. He received his Ph.D. in clinical pharmacy from Purdue University and his B.S. in pharmacy from the University of Arkansas.

Drew is the Managing Director of Lightchain Capital, LLC, the family office for Scottrade Founder and former Chief Executive Officer Rodger Riney. At Lightchain, Drew is responsible for venture capital investments in the life science and technology sectors. He also assists the Riney Foundations with their philanthropic endeavors. Previously, Drew served as the Chief Operating Officer and Chief Financial Officer at Scottrade Financial Services, Inc. He led the Company’s operations, technology, operations, finance, and strategic planning functions and worked at the Company for over a decade. Mr. Dennison led the sale of Scottrade to TD Ameritrade, then co- led the integration project, successfully combining the two companies. In addition, Mr. Dennison serves on the board of CareVet Holdings, ArchOncology, NextRNA and Mana Therapeutics.

Dr. Thomas is a native of Louisiana and practices in his home city of New Orleans. He graduated medical school from Louisiana State University in New Orleans. He finished his residency in Neurological Surgery at Louisiana State University in New Orleans and completed specialized additional training in complex and minimally invasive spinal procedures in Memphis, Tennessee under the direction of Kevin T. Foley, M.D.

He has lectured about spinal procedures on five continents and has had interactions with hundreds of surgeons from around the world. He is recognized as an innovator having been involved in the development and commercialization of many medical devices and technologies. He continues to be active with industry in the latest developments of minimally invasive spine procedures and regenerative medicine technologies so his patients may receive the most advanced spinal care in the world.

Dr. Thomas has been a successful investor in multiple early technology, biotech, and medical device companies with several successful exits. He has led multiple fundraising rounds in the biotech space.

He is the Co-founder, Chairman of the Board, and Medical Director of Crescent City Surgical Centre, a multispecialty surgical hospital serving the greater New Orleans area. Additionally, he serves as Managing member of Southern Brain & Spine, a multispecialty practice focusing on diseases of the brain and spine. He currently serves as a Director for Discgenics Inc., a late stage cell therapy company focusing on the treatment of painful degenerative disc disease of the lumbar spine, and Geneoscopy Inc., a late stage medical diagnostic company for the detection of colorectal cancer. He is a medical adviser for Climbr, Inc and Neurogami Medical. He serves as a Director for Louisiana State University Health Sciences Center Foundation and is on multiple committees for the Foundation. He is Past President of the Louisiana Association of Neurological Surgeons. He has served on multiple committees for the American Association of Neurological Surgeons including as a director for (AANS) Political Action Committee. He is a member of the Louisiana Office of Worker’s Compensation Medical Advisory Committee establishing the treatment guidelines for injured workers in Louisiana. He has lectured and taught courses for multiple professional organizations throughout the world regarding advanced surgical techniques and treatment of patients with spinal disorders.

Don brings more than 40 years of executive leadership experience in both emerging and Fortune 500 companies to Geneoscopy’s advisory board. Most recently, Don served as President and CEO of Biotheranostics up until its acquisition by Hologic in February 2021. Prior to that, Don was President, CEO and Director at Good Start Genetics. Don also served as President and CEO of Exact Sciences, where he helped oversee the company’s initial public offering. Don has also held multiple senior leadership positions at companies such as LabCorp, Quest Diagnostics, and SmithKline Beecham, where he built a strong track record in strategy development, team building, and market planning and execution.

Dr. Chaudhuri, MD, PhD, is an Assistant Professor in Radiation Oncology and a physician-scientist who treats lung cancer. Dr. Chaudhuri completed his MD at Stanford, PhD at Caltech, and undergraduate degrees at MIT. He completed his residency in Radiation Oncology at the Stanford Cancer Institute, where he did postdoctoral work under the Holman Pathway with Dr. Maximilian Diehn and Dr. Ash Alizadeh, showing that circulating tumor DNA (ctDNA) can serve as a biomarker for molecular residual disease (MRD) after curative-intent lung cancer treatment. Currently, he operates his own research lab at WUSM that is developing liquid biopsy biomarkers for cancer using ctDNA. Dr. Chaudhuri is one of the most innovative researchers in the field of cancer genomics and is using his expertise to inform Geneoscopy’s current research and future studies.

Dr. Tynan is a seasoned biotechnology entrepreneur with a focus on business development, startup entrepreneurship, fundraising, and strategic business planning for clinical diagnostic companies and investors. She has a breadth of experience in development and commercialization of new technologies for clinical diagnostics including diagnostic reimbursement, financial analysis, operations, and product development. As a consultant, Katherine has worked with a number of early stage and established diagnostic companies guiding them through product development choices, market entry strategies, funding (>$100M raised), and a diverse range of business development transactions from licensing deals, to sourcing companies for investments/acquisitions and positioning companies for sale. Katherine holds a Ph.D. in Human Genetics from the University of Calgary, Canada and a B.S. (Hons) in Microbiology from University College Galway, Ireland.

Dr. Catinis received his medical degree from Damascus University School of Medicine in 1989. He performed his Gastroenterology Fellowship at LSU from 1995 to 1997. He then completed training in transplant hepatology and biliary endoscopy at LSU from 1997 to 1998.

Dr. Catinis held the position of Medical Director of the Liver Transplantation Program at LSU from 1998 to 2000, where he taught and supervised physicians in training. He is a Fellow of the American College of Gastroenterology and held memberships in other medical organizations, including the American Medical Association, American College of Physicians and American Gastroenterology Association. Dr. Catinis is currently Medical Director of the New Orleans Research Institute and has been involved in clinical research for over fifteen years. Since January 2021, Dr Catinis holds the position of the GI Alliance Education Program Director.

Dr. Catinis has authored and co-authored numerous articles in the field of gastroenterology and has received multiple awards for his work from various medical societies.